{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T13:57:22Z","timestamp":1785938242371,"version":"3.56.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.clgc.2025.102407","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:10:31Z","timestamp":1754439031000},"page":"102407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Active Surveillance in Intermediate-Risk Prostate Cancer: A Contemporary Synthesis of Evidence"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9639-4486","authenticated-orcid":false,"given":"Fausto","family":"Petrelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Dottorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Parsani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ceresoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Taglialatela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Pampado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Serino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostina","family":"De Stefani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Trevisan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Riboldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Bruschieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivano","family":"Vavassori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.clgc.2025.102407_bib0001","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.juro.2013.05.054","article-title":"Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer","volume":"190","author":"Loeb","year":"2013","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.clgc.2025.102407_bib0002","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.euo.2024.07.003","article-title":"Has active surveillance for prostate cancer become safer? Lessons learned from a global clinical registry","volume":"8","author":"Bangma","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"8","key":"10.1016\/j.clgc.2025.102407_bib0003","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.29760","article-title":"Trends in active surveillance for men with intermediate-risk prostate cancer","volume":"7","author":"Diven","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"13","key":"10.1016\/j.clgc.2025.102407_bib0004","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/pros.23040","article-title":"Identification of pathologically favorable disease in intermediate-risk prostate cancer patients: implications for active surveillance candidates selection","volume":"75","author":"Gandaglia","year":"2015","journal-title":"Prostate"},{"key":"10.1016\/j.clgc.2025.102407_bib0005","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.euros.2023.04.006","article-title":"Variations in the uptake of active surveillance for prostate cancer and its impact on outcomes","volume":"52","author":"Ahlberg","year":"2023","journal-title":"Eur Urol Open Sci"},{"issue":"2","key":"10.1016\/j.clgc.2025.102407_bib0006","first-page":"427","article-title":"Active surveillance of grade group 2 prostate cancer: oncological outcomes from a contemporary European cohort","volume":"8","author":"Baboudjian","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2025.102407_bib0007","doi-asserted-by":"crossref","first-page":"e814","DOI":"10.1016\/j.clgc.2019.05.005","article-title":"Active surveillance versus radical prostatectomy in favorable-risk localized prostate cancer","volume":"17","author":"Thomsen","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2025.102407_bib0008","article-title":"Active surveillance in favorable intermediate-risk prostate cancer: a single-center experience","volume":"34","author":"Bandelier","year":"2024","journal-title":"Fr J Urol"},{"issue":"2","key":"10.1016\/j.clgc.2025.102407_bib0009","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41391-024-00888-y","article-title":"Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing","volume":"28","author":"Lenz","year":"2025","journal-title":"Prostate Can Prostatic Dis"},{"issue":"6","key":"10.1016\/j.clgc.2025.102407_bib0010","article-title":"Quantification of Gleason pattern 4 metrics identifies pathologic progression in patients with grade group 2 prostate cancer on active surveillance","volume":"22","author":"Perera","year":"2024","journal-title":"Clin Genitourin Can"},{"issue":"23","key":"10.1016\/j.clgc.2025.102407_bib0011","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1002\/cncr.33824","article-title":"Active surveillance for intermediate-risk prostate cancer in African American and non-Hispanic white men","volume":"127","author":"Courtney","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2025.102407_bib0012","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.urology.2021.05.068","article-title":"Outcomes of active surveillance for men with intermediate risk prostate cancer: a population-based analysis","volume":"155","author":"Chandrasekar","year":"2021","journal-title":"Urology"},{"issue":"7","key":"10.1016\/j.clgc.2025.102407_bib0013","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1007\/s00345-020-03485-5","article-title":"No detrimental effect of a positive family history on postoperative upgrading and upstaging in men with low risk and favourable intermediate-risk prostate cancer: implications for active surveillance","volume":"39","author":"Herkommer","year":"2021","journal-title":"World J Urol"},{"issue":"3","key":"10.1016\/j.clgc.2025.102407_bib0014","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.euo.2018.03.015","article-title":"Active surveillance for prostate cancer in a real-life cohort: comparing outcomes for PRIAS-eligible and PRIAS-ineligible patients","volume":"1","author":"Soeterik","year":"2018","journal-title":"Eur Urol Oncol"},{"issue":"11","key":"10.1016\/j.clgc.2025.102407_bib0015","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1111\/j.1464-410X.2012.11434.x","article-title":"Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer","volume":"110","author":"Bul","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2025.102407_bib0016","article-title":"Regional differences in patient age and prostate cancer characteristics and rates of treatment modalities in favorable and unfavorable intermediate risk prostate cancer across United States SEER registries","volume":"74","author":"Wenzel","year":"2021","journal-title":"Can Epidemiol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102407_bib0017","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s10147-021-02041-4","article-title":"Deferred radical prostatectomy in patients who initially elected for active surveillance: a multi-institutional, prospective, observational cohort of the PRIAS-JAPAN study","volume":"27","author":"Tohi","year":"2022","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2025.102407_bib0018","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.juro.2018.04.078","article-title":"Long-term outcomes after deferred radical prostatectomy in men initially treated with active surveillance","volume":"200","author":"Godtman","year":"2018","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102407_bib0019","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.euf.2016.06.001","article-title":"Contemporary management of prostate cancer patients suitable for active surveillance: a North American population-based study","volume":"4","author":"Moschini","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"7","key":"10.1016\/j.clgc.2025.102407_bib0020","doi-asserted-by":"crossref","first-page":"329.e13","DOI":"10.1016\/j.urolonc.2015.04.004","article-title":"Heterogeneity in D'Amico classification-based low-risk prostate cancer: differences in upgrading and upstaging according to active surveillance eligibility","volume":"33","author":"Schiffmann","year":"2015","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102407_bib0021","doi-asserted-by":"crossref","first-page":"154","DOI":"10.21037\/tau-20-994","article-title":"Cause-specific mortality of low and selective intermediate-risk prostate cancer patients with active surveillance or watchful waiting","volume":"10","author":"Wu","year":"2021","journal-title":"Transl Androl Urol"},{"issue":"7","key":"10.1016\/j.clgc.2025.102407_bib0022","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1007\/s12094-018-02000-y","article-title":"Outcomes and prognostic factors in intermediate-risk prostate cancer: multi-institutional analysis of the Spanish RECAP database","volume":"21","author":"Herv\u00e1s","year":"2019","journal-title":"Clin Transl Oncol"},{"issue":"30","key":"10.1016\/j.clgc.2025.102407_bib0023","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.1200\/JCO.2008.21.2613","article-title":"Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort","volume":"27","author":"Shappley","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2025.102407_bib0024","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.eururo.2016.04.021","article-title":"Quantified clinical risk change as an end point during prostate cancer active surveillance","volume":"72","author":"Leapman","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102407_bib0025","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S1470-2045(10)70146-7","article-title":"Mortality results from the Goteborg randomised population-based prostate-cancer screening trial","volume":"11","author":"Hugosson","year":"2010","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2025.102407_bib0026","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.eururo.2015.06.011","article-title":"Immediate versus delayed radical prostatectomy: updated outcomes following active surveillance of prostate cancer","volume":"68","author":"Filippou","year":"2015","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.clgc.2025.102407_bib0027","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.acuro.2018.04.005","article-title":"Immediate versus delayed prostatectomy and the fate of patients who progress to a higher risk disease on active surveillance","volume":"43","author":"Mallya","year":"2019","journal-title":"Actas Urol Esp (Engl Ed)"},{"issue":"3","key":"10.1016\/j.clgc.2025.102407_bib0028","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/JU.0000000000000247","article-title":"Evaluating the safety of active surveillance: outcomes of deferred radical prostatectomy after an initial period of surveillance","volume":"202","author":"Balakrishnan","year":"2019","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.clgc.2025.102407_bib0029","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1097\/JU.0000000000001313","article-title":"The long-term risks of metastases in men on active surveillance for early stage prostate cancer","volume":"204","author":"Maggi","year":"2020","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.clgc.2025.102407_bib0030","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.eururo.2016.03.048","article-title":"Long-term results of active surveillance in the G\u00f6teborg randomized, population-based prostate cancer screening trial","volume":"70","author":"Godtman","year":"2016","journal-title":"Eur Urol"},{"issue":"45","key":"10.1016\/j.clgc.2025.102407_bib0031","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/jncimonographs\/lgs042","article-title":"Active surveillance: the Canadian experience with an \"inclusive approach\"","volume":"2012","author":"Klotz","year":"2012","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"1","key":"10.1016\/j.clgc.2025.102407_bib0032","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.eururo.2012.08.001","article-title":"Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study","volume":"63","author":"Rider","year":"2013","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.clgc.2025.102407_bib0033","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.euo.2018.08.004","article-title":"Recommendations of active surveillance for intermediate-risk prostate cancer: results from a National Survey of Radiation Oncologists and Urologists","volume":"2","author":"Kim","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2025.102407_bib0034","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.2014.55.1192","article-title":"Long-term follow-up of a large active surveillance cohort of patients with prostate cancer","volume":"33","author":"Klotz","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2025.102407_bib0035","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.eururo.2014.06.010","article-title":"Five-year nationwide follow-up study of active surveillance for prostate cancer","volume":"67","author":"Loeb","year":"2015","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.clgc.2025.102407_bib0036","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/cncr.32709","article-title":"Downgrading of grade group 2 intermediate-risk prostate cancer from biopsy to radical prostatectomy: comparison of outcomes and predictors to identify potential candidates for active surveillance","volume":"126","author":"Su","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2025.102407_bib0037","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/bju.15281","article-title":"Negative first follow-up prostate biopsy on active surveillance is associated with decreased risk of upgrading, suspicion of progression and converting to active treatment","volume":"128","author":"Singh","year":"2021","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.clgc.2025.102407_bib0038","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1016\/j.clgc.2020.11.003","article-title":"Improving the stratification of patients with intermediate-risk prostate cancer","volume":"19","author":"Stolzenbach","year":"2021","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2025.102407_bib0039","first-page":"E7","article-title":"Active surveillance in favorable intermediate-risk prostate cancer patients: predictors of deferred intervention and treatment choice","volume":"16","author":"Sayyid","year":"2022","journal-title":"Can Urol Assoc J"},{"issue":"23","key":"10.1016\/j.clgc.2025.102407_bib0040","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1001\/jama.2024.20580","article-title":"Active surveillance or watchful waiting for intermediate-risk prostate cancer, 2010-2020","volume":"332","author":"Ajjawi","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.clgc.2025.102407_bib0041","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12894-023-01315-5","article-title":"Active surveillance should not be routinely considered in ISUP grade group 2 prostate cancer","volume":"23","author":"Gandaglia","year":"2023","journal-title":"BMC Urol"},{"issue":"3","key":"10.1016\/j.clgc.2025.102407_bib0042","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/pcan.2016.22","article-title":"The role of lifestyle characteristics on prostate cancer progression in two active surveillance cohorts","volume":"19","author":"Vandersluis","year":"2016","journal-title":"Prostat Can Prostatic Dis"},{"issue":"1","key":"10.1016\/j.clgc.2025.102407_bib0043","article-title":"Analysis of active surveillance uptake for localized prostate cancer in Quebec in 2016: a Canadian bicentric study and comparison with 2010 data","volume":"34","author":"Dariane","year":"2024","journal-title":"Fr J Urol"},{"issue":"2","key":"10.1016\/j.clgc.2025.102407_bib0044","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/CU9.0000000000000203","article-title":"Treatment of intermediate-risk prostate cancer with active surveillance in the routine care\u2014long-term outcomes of a prospective noninterventional study (HAROW)","volume":"18","author":"Weissbach","year":"2024","journal-title":"Curr Urol"},{"issue":"9","key":"10.1016\/j.clgc.2025.102407_bib0045","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.18318","article-title":"Comparison by race of conservative management for low-risk and intermediate-risk prostate cancers in veterans from 2004 to 2018","volume":"3","author":"Parikh","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.clgc.2025.102407_bib0046","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/JU.0000000000001241","article-title":"Active surveillance for men with intermediate-risk prostate cancer","volume":"205","author":"Agrawal","year":"2021","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.clgc.2025.102407_bib0047","doi-asserted-by":"crossref","first-page":"151","DOI":"10.6004\/jnccn.2021.7065","article-title":"Metastasis and mortality in men with low- and intermediate-risk prostate cancer on active surveillance","volume":"20","author":"Courtney","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"10.1016\/j.clgc.2025.102407_bib0048","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s00345-023-04353-8","article-title":"Expanding inclusion criteria for active surveillance in intermediate-risk prostate cancer: a machine learning approach","volume":"41","author":"Baboudjian","year":"2023","journal-title":"World J Urol"},{"issue":"3","key":"10.1016\/j.clgc.2025.102407_bib0049","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.21873\/invivo.13569","article-title":"Oncological outcomes in men with favorable intermediate risk prostate cancer enrolled in active surveillance","volume":"38","author":"Pepe","year":"2024","journal-title":"In Vivo"},{"issue":"2","key":"10.1016\/j.clgc.2025.102407_bib0050","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.euf.2022.09.011","article-title":"Expanding active surveillance criteria for low- and intermediate-risk prostate cancer: can we accurately predict the risk of misclassification for patients diagnosed by multiparametric magnetic resonance imaging-targeted biopsy?","volume":"9","author":"Diamand","year":"2023","journal-title":"Eur Urol Focus"},{"issue":"7","key":"10.1016\/j.clgc.2025.102407_bib0051","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00345-015-1603-7","article-title":"Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers","volume":"33","author":"van der Poel","year":"2015","journal-title":"World J Urol"},{"issue":"18","key":"10.1016\/j.clgc.2025.102407_bib0052","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1002\/cncr.32202","article-title":"Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer","volume":"125","author":"Butler","year":"2019","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2025.102407_bib0053","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.juro.2018.09.042","article-title":"Defining intermediate risk prostate cancer suitable for active surveillance","volume":"201","author":"Loeb","year":"2019","journal-title":"J Urol"},{"issue":"30","key":"10.1016\/j.clgc.2025.102407_bib0054","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1200\/JCO.2015.62.5764","article-title":"Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer","volume":"33","author":"Tosoian","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clgc.2025.102407_bib0055","doi-asserted-by":"crossref","first-page":"388.e1","DOI":"10.1016\/j.urolonc.2023.04.024","article-title":"Patterns of multispecialty care for low- and intermediate-risk prostate cancer in the use of active surveillance","volume":"41","author":"Zambrano","year":"2023","journal-title":"Urol Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2025.102407_bib0056","doi-asserted-by":"crossref","first-page":"7964","DOI":"10.3390\/curroncol29100630","article-title":"Influence of active surveillance on Gleason score upgrade and prognosis in low- and favorable intermediate-risk prostate cancer","volume":"29","author":"Hu","year":"2022","journal-title":"Curr Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2025.102407_bib0057","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/s41391-021-00448-8","article-title":"Active surveillance in intermediate-risk prostate cancer with PSA 10\u201320 ng\/mL: pathological outcome analysis of a population-level database","volume":"25","author":"Lonergan","year":"2022","journal-title":"Prostat Can Prostatic Dis"},{"issue":"5","key":"10.1016\/j.clgc.2025.102407_bib0058","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.euo.2023.02.014","article-title":"Is active surveillance an option for the management of men with low-grade prostate cancer and a positive family history? Results from a large, single-institution series","volume":"6","author":"Leni","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2025.102407_bib0059","article-title":"Comparing active surveillance and watchful waiting with radical treatment using machine learning models among patients with prostate cancer","volume":"7","author":"Hu","year":"2023","journal-title":"JCO Clin Can Inform"},{"issue":"6","key":"10.1016\/j.clgc.2025.102407_bib0060","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.juro.2016.06.102","article-title":"Active surveillance for intermediate-risk prostate cancer: survival outcomes in the Sunnybrook experience","volume":"196","author":"Musunuru","year":"2016","journal-title":"J Urol"},{"issue":"3-4","key":"10.1016\/j.clgc.2025.102407_bib0061","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000503888","article-title":"Patients with biopsy gleason score 3 + 4 are not appropriate candidates for active surveillance","volume":"104","author":"Park","year":"2020","journal-title":"Urol Int"},{"issue":"6","key":"10.1016\/j.clgc.2025.102407_bib0062","doi-asserted-by":"crossref","first-page":"175.e1","DOI":"10.1016\/j.urolonc.2024.02.010","article-title":"Contemporary risk of biochemical recurrence after radical prostatectomy in the active surveillance era","volume":"42","author":"Das","year":"2024","journal-title":"Urol Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2025.102407_bib0063","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.eururo.2016.08.043","article-title":"Adverse disease features in Gleason score 3 + 4 \"favorable intermediate-risk\" prostate cancer: implications for active surveillance","volume":"72","author":"Morlacco","year":"2017","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.clgc.2025.102407_bib0064","doi-asserted-by":"crossref","first-page":"587","DOI":"10.5534\/wjmh.230107","article-title":"Active surveillance for Taiwanese men with localized prostate cancer: intermediate-term outcomes and predictive factors","volume":"42","author":"Hong","year":"2024","journal-title":"World J Mens Health"},{"issue":"1","key":"10.1016\/j.clgc.2025.102407_bib0065","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00345-022-04228-4","article-title":"Prostate cancer mortality rates in low- and favorable intermediate-risk active surveillance patients: a population-based competing risks analysis","volume":"41","author":"Sayyid","year":"2023","journal-title":"World J Urol"},{"issue":"5","key":"10.1016\/j.clgc.2025.102407_bib0066","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.juro.2017.11.116","article-title":"Comparison of pathological and oncologic outcomes of favorable risk Gleason score 3 + 4 and low risk Gleason score 6 prostate cancer: considerations for active surveillance","volume":"199","author":"Gearman","year":"2018","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.clgc.2025.102407_bib0067","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.juro.2017.12.049","article-title":"National Comprehensive Cancer Network\u00ae favorable intermediate-risk prostate cancer\u2014is active surveillance appropriate?","volume":"199","author":"Aghazadeh","year":"2018","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.clgc.2025.102407_bib0068","doi-asserted-by":"crossref","first-page":"416","DOI":"10.4111\/icu.20200601","article-title":"Active surveillance in males with low- to intermediate-risk localized prostate cancer: a modern prospective cohort study","volume":"62","author":"Rakauskas","year":"2021","journal-title":"Investig Clin Urol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102407_bib0069","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/JU.0000000000003012","article-title":"The use and short-term outcomes of active surveillance in men with National Comprehensive Cancer Network favorable intermediate-risk prostate cancer: the initial Michigan Urological Surgery Improvement Collaborative experience","volume":"209","author":"Paudel","year":"2023","journal-title":"J Urol"},{"issue":"11","key":"10.1016\/j.clgc.2025.102407_bib0070","doi-asserted-by":"crossref","first-page":"782.e7","DOI":"10.1016\/j.urolonc.2021.02.017","article-title":"Pathologic upgrading in favorable intermediate risk active surveillance patients: clinical heterogeneity and implications for active surveillance decision","volume":"39","author":"Sayyid","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2025.102407_bib0071","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.euros.2023.02.002","article-title":"Prognostic value of the intermediate-risk feature in men with favorable intermediate-risk prostate cancer: implications for active surveillance","volume":"50","author":"Sherer","year":"2023","journal-title":"Eur Urol Open Sci"},{"issue":"1","key":"10.1016\/j.clgc.2025.102407_bib0072","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.euf.2017.05.011","article-title":"Risk of upgrading and upstaging among 10 000 patients with gleason 3+4 favorable intermediate-risk prostate cancer","volume":"5","author":"Yang","year":"2019","journal-title":"Eur Urol Focus"},{"issue":"6","key":"10.1016\/j.clgc.2025.102407_bib0073","doi-asserted-by":"crossref","first-page":"174","DOI":"10.5489\/cuaj.6328","article-title":"The long-term outcomes of Gleason grade groups 2 and 3 prostate cancer managed by active surveillance: results from a large, population-based cohort","volume":"14","author":"Richard","year":"2020","journal-title":"Can Urol Assoc J"},{"issue":"1","key":"10.1016\/j.clgc.2025.102407_bib0074","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35684","article-title":"Alternate definitions of adverse pathology to predict a very high risk of metastasis in men with intermediate- and low-risk prostate cancer","volume":"131","author":"Castaneda","year":"2025","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2025.102407_bib0075","first-page":"427","article-title":"Active surveillance of grade group 2 prostate cancer: oncological outcomes from a contemporary European cohort","volume":"8","author":"Baboudjian","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102407_bib0076","doi-asserted-by":"crossref","first-page":"74.e1","DOI":"10.1016\/j.urolonc.2020.08.012","article-title":"Comparison of Mexican-American vs Caucasian prostate cancer active surveillance candidates","volume":"39","author":"Coll\u00e0 Ruvolo","year":"2021","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102407_bib0077","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1464-410X.2011.10681.x","article-title":"The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume","volume":"110","author":"Corcoran","year":"2012","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.clgc.2025.102407_bib0078","doi-asserted-by":"crossref","first-page":"416","DOI":"10.4111\/icu.20200601","article-title":"Active surveillance in males with low- to intermediate-risk localized prostate cancer: a modern prospective cohort study","volume":"62","author":"Rakauskas","year":"2021","journal-title":"Investig Clin Urol"},{"issue":"6","key":"10.1016\/j.clgc.2025.102407_bib0079","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2217\/bmm-2021-0479","article-title":"Development and validation of a cell cycle progression signature for decentralized testing of men with prostate cancer","volume":"16","author":"Kuhl","year":"2022","journal-title":"Biomark Med"},{"issue":"4","key":"10.1016\/j.clgc.2025.102407_bib0080","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/s41391-021-00448-8","article-title":"Active surveillance in intermediate-risk prostate cancer with PSA 10-20\u2009ng\/mL: pathological outcome analysis of a population-level database","volume":"25","author":"Lonergan","year":"2022","journal-title":"Prostat Can Prostatic Dis"},{"issue":"10","key":"10.1016\/j.clgc.2025.102407_bib0081","doi-asserted-by":"crossref","first-page":"7964","DOI":"10.3390\/curroncol29100630","article-title":"Influence of active surveillance on Gleason score upgrade and prognosis in low- and favorable intermediate-risk prostate cancer","volume":"29","author":"Hu","year":"2022","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102407_bib0082","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/JU.0000000000001241","article-title":"Active surveillance for men with intermediate risk prostate cancer","volume":"205","author":"Agrawal","year":"2021","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.clgc.2025.102407_bib0083","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1001\/jamaoncol.2014.284","article-title":"Risk group and death from prostate cancer: implications for active surveillance in men with favorable intermediate-Risk prostate cancer","volume":"1","author":"Raldow","year":"2015","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2025.102407_bib0084","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1007\/s00345-021-03717-2","article-title":"Long-term and pathological outcomes of low- and intermediate-risk prostate cancer after radical prostatectomy: implications for active surveillance","volume":"39","author":"Meissner","year":"2021","journal-title":"World J Urol"},{"issue":"9","key":"10.1016\/j.clgc.2025.102407_bib0085","doi-asserted-by":"crossref","first-page":"10931","DOI":"10.1002\/cam4.5805","article-title":"A modeling study to estimate prostate cancer-specific mortality on active surveillance for men with favorable intermediate-risk prostate cancer: results from the SEARCH cohort","volume":"12","author":"Kuhlmann","year":"2023","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.clgc.2025.102407_bib0086","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00345-024-05262-0","article-title":"Changing times: trends in risk classification, tumor upstaging, and positive surgical margins after radical prostatectomy - results from a contemporary National Cancer Database study","volume":"42","author":"Freitas","year":"2024","journal-title":"World J Urol"},{"issue":"6","key":"10.1016\/j.clgc.2025.102407_bib0087","doi-asserted-by":"crossref","first-page":"e698","DOI":"10.1016\/j.clgc.2020.04.006","article-title":"The use of multiparametric Magnetic resonance imaging for follow-up of patients included in active surveillance protocol. Can PSA density discriminate patients at different risk of reclassification?","volume":"18","author":"Roscigno","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2025.102407_bib0088","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.156040","article-title":"Gleason score down and upgrading at radical prostatectomy in targeted vs. systematic prostate biopsy: findings from an institutional cohort","volume":"271","author":"Fiorentino","year":"2025","journal-title":"Pathol Res Pract"},{"issue":"12","key":"10.1016\/j.clgc.2025.102407_bib0089","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.3390\/jcm11123473","article-title":"Could 68Ga-PSMA PET\/CT evaluation reduce the number of scheduled prostate biopsies in men enrolled in active surveillance protocols?","volume":"11","author":"Pepe","year":"2022","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.clgc.2025.102407_bib0090","article-title":"BRCA mutations and prostate cancer: should urologist improve daily clinical practice?","volume":"97","author":"Vatrano","year":"2025","journal-title":"Arch Ital Urol Androl"},{"issue":"1","key":"10.1016\/j.clgc.2025.102407_bib0091","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/ijpm.ijpm_339_24","article-title":"Computer-assisted diagnosis to improve diagnostic pathology: a review","volume":"68","author":"Caputo","year":"2025","journal-title":"Ind J Pathol Microbiol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T15:25:27Z","timestamp":1757517927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325001077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":91,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1558767325001077"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102407","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Active Surveillance in Intermediate-Risk Prostate Cancer: A Contemporary Synthesis of Evidence","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102407","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102407"}}